The 3rd RNA- Targeted Drug Discovery Summit returns as the most comprehensive and definitive event for the RNA targeting small molecule community to not only address key challenges of the field, such as successful determination and prediction of RNA structure and role in disease, but also to drive forward optimized strategies to improve target selection and gain pre-clinical proof of concept to drive the field forward towards translation into clinical development.
With numerous approaches emerging to demonstrate genuine viability in directly or indirectly targeting RNA with small molecules, join leading biopharmaceutical directors, VPs and C-level executives at the 3rd RNA- Targeted Drug Discovery Summit – your premier industry and translational focused conference dedicated to advancing pioneering RNA biology and drug discovery into a blockbuster RNA targeting small molecule therapeutic approach that improves patient outcomes.
The world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. This view is now changing given the recent progress and scientific breakthroughs in understanding the fundamental biology and function of RNA, opening the door to RNA targeted small molecule drug discovery.
Why You Should Attend the RNA- Targeted Drug Discovery Summit
• Explore how to optimize medicinal chemistry insights and RNA biology to enhance robust translation with The Scripps Research Institute, Anima Biotech and Arrakis Therapeutics
• Successfully target RNA via interfering with RNA-protein interactions/ Epitranscriptomics with insights from Storm Therapeutics, Accent Therapeutics and Saverna Therapeutics
• Expand your knowledge of RNA structure, function and role in disease with insights from Yale University, H3 Biomedicine and Whitehead Institute for Biomedical Research
• Advance identification and validation of viable RNA target sites for therapeutic intervention with insights from PTC Therapeutics and Duke University
• Overcome binding, selectivity and drug-like challenges of small molecules targeting RNA with insights from Roche, University of California San Diego and Novartis
Visit the website and download your complimentary event guide to find out more!
Category: Conferences | Science, Health and Medicine | Pharmaceuticals
Industry Pricing - Conference + Workshop Day (First Release): USD 2307.0,
Industry Pricing - Conference + Workshop Day (Second Release): USD 2552.0,
Industry Pricing - Conference + Workshop Day (Third Release): USD 2797.0,
Industry Pricing - Conference + Workshop Day (Fourth Release): USD 3042.0,
Industry Pricing - Conference + Workshop Day (Final): USD 3287.0,
Academic Pricing - Conference + Workshop Day (First Release): USD 1817.0,
Academic Pricing - Conference + Workshop Day (Second Release): USD 2062.0,
Academic Pricing - Conference + Workshop Day (Third Release): USD 2307.0,
Academic Pricing - Conference + Workshop Day (Fourth Release): USD 2552.0,
Academic Pricing - Conference + Workshop Day (Final): USD 2797.0
Speakers: Matthew Disney, Professor, Department of Chemistry and Neuroscience, The Scripps Research Institute and Scientific Founder of Expansion Therapeutics, Katie Warner, Vice President of RNA Biology and Co- Founder, Ribometrix, Melissa Moore, Chief Scientific Officer, Moderna, Jen Petter, Founder and Chief Scientific Officer, Arrakis Therapeutics, Travis Wager, President and Chief Scientific Officer, Rgenta Therapeutics, Simon Xi, Chief Executive Officer, Rgenta Therapeutics, Yochi Slonim, Chief Executive Officer and Co-Founder, Anima Biotech, Marcel Blommers, Chief Scientific Officer, Saverna Therapeutics, Amanda Hargrove, Associate Professor, Duke University, Matt Woll, Vice President and Head of Chemistry, PTC Therapeutics, Chris Burge, Professor of Biology, Massachusetts Institute of Technology, Tim Luker, Senior Director External Innovation, Eli Lilly and Company, Peggy Thompson, Executive Director of Translational Medicine, eFFECTOR Therapeutics, Anna Marie Pyle, Sterling Professor, Yale University and HHMI Investigator, Nicholas Larsen, Director of Lead Discovery, H3 Biomedicine, Silvi Rouskin, Principal Investigator and Whitehead Fellow, Whitehead Institute for Biomedical Research, Robert Copeland, President and Chief Scientific Officer, Accent Therapeutics, Samie Jaffrey, Pharmacology Greenberg-Starr Professor, Weill Cornell Medicine, Adrian Krainer, Professor, Cold Spring Harbor Laboratory, Wesley Blackaby, Vice President of Chemistry, Storm Therapeutics, Nikola Trbovic, Principal and Executive Director, Pfizer Ventures, Razvan Nutiu, Senior Principal Scientist, Novartis, Gene Yeo, Professor, University of California San Diego, Tony Mustoe, Assistant Professor and CPRIT Scholar, Baylor College of Medicine, Gabe Sholder, Senior Scientist, AbbVie, Hasane Ratni, Expert Scientist and Project Leader, Roche